Circulating free fatty acids, insulin, and glucose during chemical stimulation of hypothalamus in rats [PDF]
, 1984 The aim of this study was to investigate plasma free fatty acids (FFA), insulin, and blood glucose during chemical stimulation of the lateral and ventromedial hypothalamic areas (LHA and VMH) in rats.
Damsma, G., +3 more
core +1 more source
Intensive Insulin Therapy (Basal-Bolus)
American Journal of Therapeutics, 2020 Background: Intensive insulin therapy (IIT) aims at achieving near-normal glycemic control and usually uses a basal-bolus (BB) schema to mimic physiologic insulin secretion. Areas of Uncertainty: The treatment burden of IIT should be outweighed by improved glycemic control and ...
Chico, A, Corcoy, R
openaire +4 more sources
Modern basal insulins: an ongoing story or the start of a new era?
Сахарный диабет, 2015 Basal insulin represents an essential tool in the treatment of both type 1 and type 2 diabetes mellitus. The development of insulin analogues has improved the possibilities of diabetes treatment.
Ivan Ivanovich Dedov
doaj +1 more source
Molecular Metabolism, 2022 Objectives: Pancreatic beta cells secrete insulin postprandially and during fasting to maintain glucose homeostasis. Although glucose-stimulated insulin secretion (GSIS) has been extensively studied, much less is known about basal insulin secretion. Here,
Liu Yang +11 more
doaj +1 more source
A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks. DUAL VIII, a randomized trial designed to resemble clinical practice [PDF]
, 2020 This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N =
Aroda, V. R. +7 more
core +1 more source
79. Basal-bolus insulin compared to premixed insulin in cardiac outpatients with type 2 diabetes
Journal of the Saudi Heart Association, 2016 Diabetes is a highly prevalent chronic disease worldwide. It was observed inKing Abdul-Aziz Cardiac Centre (KACC) that, subjects treated with basal bolus insulin showed better glycemic control than premixed insulin.
A. Enoz
doaj +1 more source
Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. [PDF]
PLoS ONE, 2018 We assessed the cost-effectiveness of the glucagon-like peptide 1 receptor agonists liraglutide 1.8 mg and lixisenatide 20 μg (both added to basal insulin) in patients with type 2 diabetes (T2D) in Sweden.The Swedish Institute for Health Economics cohort
Åsa Ericsson +4 more
doaj +1 more source
Metabolites, 2021 Insulin degludec/insulin aspart (IDegAsp) is a novel co-formulation of 70% insulin degludec and 30% insulin aspart. The present meta-analysis was conducted to assess the efficacy and safety of IDegAsp compared with a conventional premixed insulin or ...
Shinje Moon +6 more
doaj +1 more source
The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver [PDF]
, 2019 Secreted frizzled-related protein (sFRP) 4 is an adipokine with increased expression in white adipose tissue from obese subjects with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).
Al-Hasani, Hadi +12 more
core +1 more source
Diabetology & Metabolic Syndrome, 2018 Introduction This observational study aimed to assess the effectiveness of lixisenatide as add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes.
Tomislav Božek +6 more
doaj +1 more source